AGP
RAPT

Artia Global Partners’s RAPT Therapeutics RAPT Stock Holding History

Artia Global Partners’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-17,164
Closed -$1.23M – 54
2024
Q1 		$1.23M Buy
17,164
+14,709
+599% +$2.05M 0.25% 36
2023
Q4 		$488K Buy
+2,455
New +$304K 0.14% 26

Other funds holding RAPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Artia Global Partners's RAPT Position: Q2 2024 in Review

Artia Global Partners sold out of RAPT Therapeutics (RAPT) in Q2 2024, closing a stake of 17,164 shares — an estimated $1.23M sold.

Artia Global Partners first reported a position in RAPT in Q4 2023 and held it in 2 quarters. The position peaked at $1.23M in Q1 2024. 103 funds tracked by Wall St. Rank hold RAPT as of Q2 2024.

  • Artia Global Partners reported no remaining RAPT Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Artia Global Partners sold 17,164 RAPT Therapeutics shares in Q2 2024, an estimated $1.23M.
  • Artia Global Partners first reported a position in RAPT Therapeutics in Q4 2023 and held it in 2 quarters.
  • Artia Global Partners's RAPT Therapeutics position peaked at $1.23M in Q1 2024.
  • 103 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q2 2024.

Based on Artia Global Partners's 13F filing for Q2 2024, filed 14 Aug 2024.